OR WAIT null SECS
March 20, 2019
Alcami Biologics formed to meet market demands for biological drug development services.
Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.
March 15, 2019
The company received $4.8 million from the Bill & Melinda Gates Foundation to accelerate global health research in the development of vaccines and antibody-based treatments for infectious diseases.
March 12, 2019
The agency prioritized the review of the generic angiotensin II receptor blocker to help relieve the shortage of valsartan due to recent recalls.
March 08, 2019
Procarta Biosystems has received investment from Novo Holdings REPAIR Impact Fund to the tune of €1.5 million, which will be used to develop a new class of antibiotics to tackle AMR.
FDA Commissioner Gottlieb released a statement on the agency’s efforts to refine the naming convention for biosimilars to balance competition and to help ensure patient safety.
March 07, 2019
Janssen’s Spravato (esketamine) gains approval with restricted distribution guidelines.
Hetero Labs recalls losartan potassium tablets due to presence of N-Nitroso-N-methyl-4-aminobutyric acid.
March 05, 2019
The companies will use GeoVax’s vaccine technology to develop malaria vaccine candidates.
The acquisition will establish a clinical pipeline for Biogen of gene-therapy candidates in ophthalmology.